Search

Your search keyword '"van Amerongen, Martinus J."' showing total 28 results
Start Over Author "van Amerongen, Martinus J."
28 results on '"van Amerongen, Martinus J."'

1. Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation

Author

Michiel Zeeuw, J., Wesdorp, Nina J., Ali, Mahsoem, Bakker, Anne-Joëlle J.J., Voigt, Kelly R., Starmans, Martijn P.A., Roor, Joran, Kemna, Ruby, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M.G.C., Moos, Shira I., van Dieren, Susan, van Amerongen, Martinus J., Bond, Marinde J.G., Chapelle, Thiery, van Dam, Ronald M., Engelbrecht, Marc R.W., Gerhards, Michael F., van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Quintus Molenaar, I., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., de Wilt, Johannes H.W., Verpalen, Inez M., Stoker, Jaap, Grunhagen, Dirk J., Swijnenburg, Rutger-Jan, Punt, Cornelis J.A., Huiskens, Joost, Verhoef, Cornelis, and Kazemier, Geert

Published
2024
Full Text
View/download PDF

2. Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Author

Bond, Marinde J. G., Kuiper, Babette I., Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J., Chapelle, Thiery, Dejong, Cornelis H. C., Engelbrecht, Marc R. W., Gerhards, Michael F., Grünhagen, Dirk J., van Gulik, Thomas, Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F. M., Leclercq, Wouter K. G., Liem, Mike S. L., van Lienden, Krijn P., Molenaar, I. Quintus, Neumann, Ulf P., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H. W., Kazemier, Geert, May, Anne M., Punt, Cornelis J. A., and Swijnenburg, Rutger-Jan

Published
2023
Full Text
View/download PDF

3. Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases

Author

Wesdorp, Nina J., Zeeuw, J. Michiel, Postma, Sam C. J., Roor, Joran, van Waesberghe, Jan Hein T. M., van den Bergh, Janneke E., Nota, Irene M., Moos, Shira, Kemna, Ruby, Vadakkumpadan, Fijoy, Ambrozic, Courtney, van Dieren, Susan, van Amerongen, Martinus J., Chapelle, Thiery, Engelbrecht, Marc R. W., Gerhards, Michael F., Grunhagen, Dirk, van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Liem, Mike S. L., van Lienden, Krijn P., Molenaar, I. Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H. W., Marquering, Henk A., Stoker, Jaap, Swijnenburg, Rutger-Jan, Punt, Cornelis J. A., Huiskens, Joost, and Kazemier, Geert

Published
2023
Full Text
View/download PDF

4. Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation

Author

Hart- en Vaatziekten Team A, Epi Kanker Team B, Cancer, MS CGO, Zorgeenheid Kinderchirurgie Medisch, Researchgr. Beeldg. Moleculaire Interv., Michiel Zeeuw, J., Wesdorp, Nina J., Ali, Mahsoem, Bakker, Anne Joëlle J.J., Voigt, Kelly R., Starmans, Martijn P.A., Roor, Joran, Kemna, Ruby, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M.G.C., Moos, Shira I., van Dieren, Susan, van Amerongen, Martinus J., Bond, Marinde J.G., Chapelle, Thiery, van Dam, Ronald M., Engelbrecht, Marc R.W., Gerhards, Michael F., van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Quintus Molenaar, I., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., de Wilt, Johannes H.W., Verpalen, Inez M., Stoker, Jaap, Grunhagen, Dirk J., Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, Verhoef, Cornelis, Kazemier, Geert, Hart- en Vaatziekten Team A, Epi Kanker Team B, Cancer, MS CGO, Zorgeenheid Kinderchirurgie Medisch, Researchgr. Beeldg. Moleculaire Interv., Michiel Zeeuw, J., Wesdorp, Nina J., Ali, Mahsoem, Bakker, Anne Joëlle J.J., Voigt, Kelly R., Starmans, Martijn P.A., Roor, Joran, Kemna, Ruby, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M.G.C., Moos, Shira I., van Dieren, Susan, van Amerongen, Martinus J., Bond, Marinde J.G., Chapelle, Thiery, van Dam, Ronald M., Engelbrecht, Marc R.W., Gerhards, Michael F., van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Quintus Molenaar, I., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., de Wilt, Johannes H.W., Verpalen, Inez M., Stoker, Jaap, Grunhagen, Dirk J., Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, Verhoef, Cornelis, and Kazemier, Geert

Published
2024

5. Prognostic value of total tumor volume in patients with colorectal liver metastases:A secondary analysis of the randomized CAIRO5 trial with external cohort validation

Author

Michiel Zeeuw, J., Wesdorp, Nina J., Ali, Mahsoem, Bakker, Anne Joëlle J.J., Voigt, Kelly R., Starmans, Martijn P.A., Roor, Joran, Kemna, Ruby, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M.G.C., Moos, Shira I., van Dieren, Susan, van Amerongen, Martinus J., Bond, Marinde J.G., Chapelle, Thiery, van Dam, Ronald M., Engelbrecht, Marc R.W., Gerhards, Michael F., van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Quintus Molenaar, I., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., de Wilt, Johannes H.W., Verpalen, Inez M., Stoker, Jaap, Grunhagen, Dirk J., Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, Verhoef, Cornelis, Kazemier, Geert, Michiel Zeeuw, J., Wesdorp, Nina J., Ali, Mahsoem, Bakker, Anne Joëlle J.J., Voigt, Kelly R., Starmans, Martijn P.A., Roor, Joran, Kemna, Ruby, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M.G.C., Moos, Shira I., van Dieren, Susan, van Amerongen, Martinus J., Bond, Marinde J.G., Chapelle, Thiery, van Dam, Ronald M., Engelbrecht, Marc R.W., Gerhards, Michael F., van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Quintus Molenaar, I., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., de Wilt, Johannes H.W., Verpalen, Inez M., Stoker, Jaap, Grunhagen, Dirk J., Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, Verhoef, Cornelis, and Kazemier, Geert

Abstract

Background:This study aimed to assess the prognostic value of total tumor volume (TTV) for early recurrence (within 6 months) and overall survival (OS) in patients with colorectal liver metastases (CRLM), treated with induction systemic therapy followed by complete local treatment.Methods: Patients with initially unresectable CRLM from the multicenter randomized phase 3 CAIRO5 trial (NCT02162563) who received induction systemic therapy followed by local treatment were included. Baseline TTV and change in TTV as response to systemic therapy were calculated using the CT scan before and the first after systemic treatment, and were assessed for their added prognostic value. The findings were validated in an external cohort of patients treated at a tertiary center. Results:In total, 215 CAIRO5 patients were included. Baseline TTV and absolute change in TTV were significantly associated with early recurrence (P = 0.005 and P = 0.040, respectively) and OS in multivariable analyses (P = 0.024 and P = 0.006, respectively), whereas RECIST1.1 was not prognostic for early recurrence (P = 0.88) and OS (P = 0.35). In the validation cohort (n = 85), baseline TTV and absolute change in TTV remained prognostic for early recurrence (P = 0.041 and P = 0.021, respectively) and OS in multivariable analyses (P < 0.0001 and P = 0.012, respectively), and showed added prognostic value over conventional clinicopathological variables (increase C-statistic, 0.06; 95 % CI, 0.02 to 0.14; P = 0.008). Conclusion: Total tumor volume is strongly prognostic for early recurrence and OS in patients who underwent complete local treatment of initially unresectable CRLM, both in the CAIRO5 trial and the validation cohort. In contrast, RECIST1.1 did not show prognostic value for neither early recurrence nor OS.

Published
2024

8. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Author

Bond, Marinde J G, primary, Bolhuis, Karen, additional, Loosveld, Olaf J L, additional, de Groot, Jan Willem B, additional, Droogendijk, Helga, additional, Helgason, Helgi H, additional, Hendriks, Mathijs P, additional, Klaase, Joost M, additional, Kazemier, Geert, additional, Liem, Mike S L, additional, Rijken, Arjen M, additional, Verhoef, Cornelis, additional, de Wilt, Johannes H W, additional, de Jong, Koert P, additional, Gerhards, Michael F, additional, van Amerongen, Martinus J, additional, Engelbrecht, Marc R W, additional, van Lienden, Krijn P, additional, Molenaar, I Quintus, additional, de Valk, Bart, additional, Haberkorn, Brigitte C M, additional, Kerver, Emile D, additional, Erdkamp, Frans, additional, van Alphen, Robbert J, additional, Mathijssen-van Stein, Daniëlle, additional, Komurcu, Aysun, additional, Lopez-Yurda, Marta, additional, Swijnenburg, Rutger-Jan, additional, Punt, Cornelis J A, additional, Van Gulik, Thomas, additional, Huiskens, Joost, additional, Van Tinteren, Harm, additional, Dejong, Cornelis H.C., additional, Grünhagen, Dirk J., additional, Patijn, Gijs A., additional, Ruers, Theo J.M., additional, Chapelle, Thiery, additional, Hermans, John J., additional, Leclercq, Wouter K.G., additional, Valkenburg-van Iersel, Liselot B.J., additional, Grootscholten, Cecile, additional, Van Dodewaard-de Jong, Joyce M., additional, Vincent, Jeroen, additional, Houtsma, Danny, additional, Los, Maartje, additional, Den Boer, Marien, additional, Trajkovic-Vidakovic, Marija, additional, Van Voorthuizen, Theo, additional, Koopman, Miriam, additional, Vestjens, Johanneke H.M.J.V., additional, Torrenga, Hans, additional, Mekenkamp, Leonie J., additional, Veldhuis, Gerrit Jan, additional, Polee, Marco B., additional, Dohmen, Serge E., additional, Schut, Heidi, additional, Vulink, Annelie J.E., additional, Van Halteren, Henk K., additional, Oulad Hadj, Jamal, additional, Schiphorst, Pieter-Paul J.B.M., additional, and Hoekstra, Ronald, additional

Published
2023
Full Text
View/download PDF

10. ASO Visual Abstract: Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases—Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Author

Bond, Marinde J. G., primary, Kuiper, Babette I., additional, Bolhuis, Karen, additional, Komurcu, Aysun, additional, van Amerongen, Martinus J., additional, Chapelle, Thiery, additional, Dejong, Cornelis H. C., additional, Engelbrecht, Marc R. W., additional, Gerhards, Michael F., additional, Grünhagen, Dirk J., additional, van Gulik, Thomas, additional, Hermans, John J., additional, de Jong, Koert P., additional, Klaase, Joost M., additional, Kok, Niels F. M., additional, Leclercq, Wouter K. G., additional, Liem, Mike S. L., additional, van Lienden, Krijn P., additional, Quintus Molenaar, I., additional, Neumann, Ulf P., additional, Patijn, Gijs A., additional, Rijken, Arjen M., additional, Ruers, Theo M., additional, Verhoef, Cornelis, additional, de Wilt, Johannes H. W., additional, Kazemier, Geert, additional, May, Anne M., additional, Punt, Cornelis J. A., additional, and Swijnenburg, Rutger-Jan, additional

Published
2023
Full Text
View/download PDF

11. Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases:Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Author

Bond, Marinde J.G., Kuiper, Babette I., Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J., Chapelle, Thiery, Dejong, Cornelis H.C., Engelbrecht, Marc R.W., Gerhards, Michael F., Grünhagen, Dirk J., van Gulik, Thomas, Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I. Quintus, Neumann, Ulf P., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H.W., Kazemier, Geert, May, Anne M., Punt, Cornelis J.A., Swijnenburg, Rutger Jan, Bond, Marinde J.G., Kuiper, Babette I., Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J., Chapelle, Thiery, Dejong, Cornelis H.C., Engelbrecht, Marc R.W., Gerhards, Michael F., Grünhagen, Dirk J., van Gulik, Thomas, Hermans, John J., de Jong, Koert P., Klaase, Joost M., Kok, Niels F.M., Leclercq, Wouter K.G., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I. Quintus, Neumann, Ulf P., Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H.W., Kazemier, Geert, May, Anne M., Punt, Cornelis J.A., and Swijnenburg, Rutger Jan

Abstract

Background: Consensus on resectability criteria for colorectal cancer liver metastases (CRLM) is lacking, resulting in differences in therapeutic strategies. This study evaluated variability of resectability assessments and local treatment plans for patients with initially unresectable CRLM by the liver expert panel from the randomised phase III CAIRO5 study. Methods: The liver panel, comprising surgeons and radiologists, evaluated resectability by predefined criteria at baseline and 2-monthly thereafter. If surgeons judged CRLM as resectable, detailed local treatment plans were provided. The panel chair determined the conclusion of resectability status and local treatment advice, and forwarded it to local surgeons. Results: A total of 1149 panel evaluations of 496 patients were included. Intersurgeon disagreement was observed in 50% of evaluations and was lower at baseline than follow-up (36% vs. 60%, p < 0.001). Among surgeons in general, votes for resectable CRLM at baseline and follow-up ranged between 0–12% and 27–62%, and for permanently unresectable CRLM between 3–40% and 6–47%, respectively. Surgeons proposed different local treatment plans in 77% of patients. The most pronounced intersurgeon differences concerned the advice to proceed with hemihepatectomy versus parenchymal-preserving approaches. Eighty-four percent of patients judged by the panel as having resectable CRLM indeed received local treatment. Local surgeons followed the technical plan proposed by the panel in 40% of patients. Conclusion: Considerable variability exists among expert liver surgeons in assessing resectability and local treatment planning of initially unresectable CRLM. This stresses the value of panel-based decisions, and the need for consensus guidelines on resectability criteria and technical approach to prevent unwarranted variability in clinical practice.

Published
2023

12. Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases

Author

MS CGO, Cancer, Epi Kanker Team B, Wesdorp, Nina J., Zeeuw, J. Michiel, Postma, Sam C.J., Roor, Joran, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M., Moos, Shira, Kemna, Ruby, Vadakkumpadan, Fijoy, Ambrozic, Courtney, van Dieren, Susan, van Amerongen, Martinus J., Chapelle, Thiery, Engelbrecht, Marc R.W., Gerhards, Michael F., Grunhagen, Dirk, van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I. Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H.W., Marquering, Henk A., Stoker, Jaap, Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, Kazemier, Geert, MS CGO, Cancer, Epi Kanker Team B, Wesdorp, Nina J., Zeeuw, J. Michiel, Postma, Sam C.J., Roor, Joran, van Waesberghe, Jan Hein T.M., van den Bergh, Janneke E., Nota, Irene M., Moos, Shira, Kemna, Ruby, Vadakkumpadan, Fijoy, Ambrozic, Courtney, van Dieren, Susan, van Amerongen, Martinus J., Chapelle, Thiery, Engelbrecht, Marc R.W., Gerhards, Michael F., Grunhagen, Dirk, van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I. Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H.W., Marquering, Henk A., Stoker, Jaap, Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, and Kazemier, Geert

Published
2023

13. ASO Visual Abstract: Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases-Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Author

Epi Kanker Team B, Cancer, MS CGO, Epi Kanker, JC onderzoeksprogramma Kanker, Bond, Marinde J G, Kuiper, Babette I, Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J, Chapelle, Thiery, Dejong, Cornelis H C, Engelbrecht, Marc R W, Gerhards, Michael F, Grünhagen, Dirk J, van Gulik, Thomas, Hermans, John J, de Jong, Koert P, Klaase, Joost M, Kok, Niels F M, Leclercq, Wouter K G, Liem, Mike S L, van Lienden, Krijn P, Quintus Molenaar, I, Neumann, Ulf P, Patijn, Gijs A, Rijken, Arjen M, Ruers, Theo M, Verhoef, Cornelis, de Wilt, Johannes H W, Kazemier, Geert, May, Anne M, Punt, Cornelis J A, Swijnenburg, Rutger-Jan, Epi Kanker Team B, Cancer, MS CGO, Epi Kanker, JC onderzoeksprogramma Kanker, Bond, Marinde J G, Kuiper, Babette I, Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J, Chapelle, Thiery, Dejong, Cornelis H C, Engelbrecht, Marc R W, Gerhards, Michael F, Grünhagen, Dirk J, van Gulik, Thomas, Hermans, John J, de Jong, Koert P, Klaase, Joost M, Kok, Niels F M, Leclercq, Wouter K G, Liem, Mike S L, van Lienden, Krijn P, Quintus Molenaar, I, Neumann, Ulf P, Patijn, Gijs A, Rijken, Arjen M, Ruers, Theo M, Verhoef, Cornelis, de Wilt, Johannes H W, Kazemier, Geert, May, Anne M, Punt, Cornelis J A, and Swijnenburg, Rutger-Jan

Published
2023

14. Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group

Author

Epi Kanker Team B, Cancer, MS CGO, Epi Kanker, JC onderzoeksprogramma Kanker, Bond, Marinde J G, Kuiper, Babette I, Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J, Chapelle, Thiery, Dejong, Cornelis H C, Engelbrecht, Marc R W, Gerhards, Michael F, Grünhagen, Dirk J, van Gulik, Thomas, Hermans, John J, de Jong, Koert P, Klaase, Joost M, Kok, Niels F M, Leclercq, Wouter K G, Liem, Mike S L, van Lienden, Krijn P, Molenaar, I Quintus, Neumann, Ulf P, Patijn, Gijs A, Rijken, Arjen M, Ruers, Theo M, Verhoef, Cornelis, de Wilt, Johannes H W, Kazemier, Geert, May, Anne M, Punt, Cornelis J A, Swijnenburg, Rutger-Jan, Epi Kanker Team B, Cancer, MS CGO, Epi Kanker, JC onderzoeksprogramma Kanker, Bond, Marinde J G, Kuiper, Babette I, Bolhuis, Karen, Komurcu, Aysun, van Amerongen, Martinus J, Chapelle, Thiery, Dejong, Cornelis H C, Engelbrecht, Marc R W, Gerhards, Michael F, Grünhagen, Dirk J, van Gulik, Thomas, Hermans, John J, de Jong, Koert P, Klaase, Joost M, Kok, Niels F M, Leclercq, Wouter K G, Liem, Mike S L, van Lienden, Krijn P, Molenaar, I Quintus, Neumann, Ulf P, Patijn, Gijs A, Rijken, Arjen M, Ruers, Theo M, Verhoef, Cornelis, de Wilt, Johannes H W, Kazemier, Geert, May, Anne M, Punt, Cornelis J A, and Swijnenburg, Rutger-Jan

Published
2023

17. Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases

Author

Wesdorp, Nina J, Kemna, Ruby, Bolhuis, Karen, van Waesberghe, Jan H T M, Nota, Irene M G C, Struik, Femke, Oulad Abdennabi, Ikrame, Phoa, Saffire S K S, van Dieren, Susan, van Amerongen, Martinus J, Chapelle, Thiery, Dejong, Cornelis H C, Engelbrecht, Marc R W, Gerhards, Michael F, Grünhagen, Dirk, van Gulik, Thomas M, Hermans, John J, de Jong, Koert P, Klaase, Joost M, Liem, Mike S L, van Lienden, Krijn P, Molenaar, I Quintus, Patijn, Gijs A, Rijken, Arjen M, Ruers, Theo M, Verhoef, Cornelis, de Wilt, Johannes H W, Swijnenburg, Rutger-Jan, Punt, Cornelis J A, Huiskens, Joost, Stoker, Jaap, Kazemier, Geert, Surgery, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, Internal medicine, Radiology and nuclear medicine, AGEM - Re-generation and cancer of the digestive system, VU University medical center, CCA - Imaging and biomarkers, Radiology & Nuclear Medicine, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Radiology and Nuclear Medicine, AGEM - Digestive immunity, APH - Methodology, Oncology, Groningen Institute for Organ Transplantation (GIOT), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Value, Affordability and Sustainability (VALUE)

Subjects
Colorectal Neoplasms/diagnostic imaging, Male, Tumor Response, Abdomen/Gastrointestinal, Tomography, X-Ray Computed/methods, Observer Performance, Metastases, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Liver Neoplasms/diagnostic imaging, Humans, Prospective Studies, Tomography, Original Research, Computer. Automation, Observer Variation, Liver Neoplasms, General Medicine, Middle Aged, X-Ray Computed/methods, Liver, Oncology, Female, Human medicine, Colorectal Neoplasms, Tomography, X-Ray Computed, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], CT
Abstract

Item does not contain fulltext Purpose To evaluate interobserver variability in the morphologic tumor response assessment of colorectal liver metastases (CRLM) managed with systemic therapy and to assess the relation of morphologic response with gene mutation status, targeted therapy, and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 measurements. Materials and Methods Participants with initially unresectable CRLM receiving different systemic therapy regimens from the randomized, controlled CAIRO5 trial (NCT02162563) were included in this prospective imaging study. Three radiologists independently assessed morphologic tumor response on baseline and first follow-up CT scans according to previously published criteria. Two additional radiologists evaluated disagreement cases. Interobserver agreement was calculated by using Fleiss κ. On the basis of the majority of individual radiologic assessments, the final morphologic tumor response was determined. Finally, the relation of morphologic tumor response and clinical prognostic parameters was assessed. Results In total, 153 participants (median age, 63 years [IQR, 56-71]; 101 men) with 306 CT scans comprising 2192 CRLM were included. Morphologic assessment performed by the three radiologists yielded 86 (56%) agreement cases and 67 (44%) disagreement cases (including four major disagreement cases). Overall interobserver agreement between the panel radiologists on morphology groups and morphologic response categories was moderate (κ = 0.53, 95% CI: 0.48, 0.58 and κ = 0.54, 95% CI: 0.47, 0.60). Optimal morphologic response was particularly observed in patients treated with bevacizumab (P = .001) and in patients with RAS/BRAF mutation (P = .04). No evidence of a relationship between RECIST 1.1 and morphologic response was found (P = .61). Conclusion Morphologic tumor response assessment following systemic therapy in participants with CRLM demonstrated considerable interobserver variability. Keywords: Tumor Response, Observer Performance, CT, Liver, Metastases, Oncology, Abdomen/Gastrointestinal Clinical trial registration no. NCT02162563 Supplemental material is available for this article. © RSNA, 2022.

Published
2022
Full Text
View/download PDF

18. Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases

Author

MS CGO, Cancer, CTC, Wesdorp, Nina J., Kemna, Ruby, Bolhuis, Karen, van Waesberghe, Jan H.T.M., Nota, Irene M.G.C., Struik, Femke, Abdennabi, Ikrame Oulad, Phoa, Saffire S.K.S., van Dieren, Susan, van Amerongen, Martinus J., Chapelle, Thiery, Dejong, Cornelis H.C., Engelbrecht, Marc R.W., Gerhards, Michael F., Grünhagen, Dirk, van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H.W., Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, Stoker, Jaap, Kazemier, Geert, MS CGO, Cancer, CTC, Wesdorp, Nina J., Kemna, Ruby, Bolhuis, Karen, van Waesberghe, Jan H.T.M., Nota, Irene M.G.C., Struik, Femke, Abdennabi, Ikrame Oulad, Phoa, Saffire S.K.S., van Dieren, Susan, van Amerongen, Martinus J., Chapelle, Thiery, Dejong, Cornelis H.C., Engelbrecht, Marc R.W., Gerhards, Michael F., Grünhagen, Dirk, van Gulik, Thomas M., Hermans, John J., de Jong, Koert P., Klaase, Joost M., Liem, Mike S.L., van Lienden, Krijn P., Molenaar, I Quintus, Patijn, Gijs A., Rijken, Arjen M., Ruers, Theo M., Verhoef, Cornelis, de Wilt, Johannes H.W., Swijnenburg, Rutger Jan, Punt, Cornelis J.A., Huiskens, Joost, Stoker, Jaap, and Kazemier, Geert

Published
2022

19. FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.

Author

Punt, Cornelis J. A., primary, Bond, Marinde J.G., additional, Bolhuis, Karen, additional, Loosveld, Olaf, additional, Helgason, Helgi H., additional, de Groot, Jan Willem, additional, Hendriks, Mathijs P., additional, Kerver, Emile D., additional, Liem, Mike S.L., additional, Rijken, Arjen M., additional, Verhoef, Cornelis, additional, de Wilt, Johannes H.W., additional, De Jong, Koert P., additional, Kazemier, Geert, additional, van Amerongen, Martinus J., additional, Engelbrecht, Marc R.W., additional, Klaase, Joost M., additional, Komurcu, Aysun, additional, Lopez-Yurda, Marta I., additional, and Swijnenburg, Rutger-Jan, additional

Published
2022
Full Text
View/download PDF

20. The Disease-Free Interval Between Resection of Primary Colorectal Malignancy and the Detection of Hepatic Metastases Predicts Disease Recurrence But Not Overall Survival

Author

Höppener, Diederik J, Nierop, Pieter M H, van Amerongen, Martinus J, Olthof, Pim B, Galjart, Boris, van Gulik, Thomas M, de Wilt, Johannes H W, Grünhagen, Dirk J, Rahbari, Nuh N, Verhoef, Cornelis, Höppener, Diederik J, Nierop, Pieter M H, van Amerongen, Martinus J, Olthof, Pim B, Galjart, Boris, van Gulik, Thomas M, de Wilt, Johannes H W, Grünhagen, Dirk J, Rahbari, Nuh N, and Verhoef, Cornelis

Abstract

INTRODUCTION: The disease-free interval (DFI) between resection of primary colorectal cancer (CRC) and diagnosis of liver metastases is considered an important prognostic indicator; however, recent analyses in metastatic CRC found limited evidence to support this notion.OBJECTIVE: The current study aims to determine the prognostic value of the DFI in patients with resectable colorectal liver metastases (CRLM).METHODS: Patients undergoing first surgical treatment of CRLM at three academic centers in The Netherlands were eligible for inclusion. The DFI was defined as the time between resection of CRC and detection of CRLM. Baseline characteristics and Kaplan-Meier survival estimates were stratified by DFI. Cox regression analyses were performed for overall (OS) and disease-free survival (DFS), with the DFI entered as a continuous measure using a restricted cubic spline function with three knots.RESULTS: In total, 1374 patients were included. Patients with a shorter DFI more often had lymph node involvement of the primary, more frequently received neoadjuvant chemotherapy for CRLM, and had higher number of CRLM at diagnosis. The DFI significantly contributed to DFS prediction (p =0.002), but not for predicting OS (p =0.169). Point estimates of the hazard ratio (95% confidence interval) for a DFI of 0 versus 12 months and 0 versus 24 months were 1.284 (1.114-1.480) and 1.444 (1.180-1.766), respectively, for DFS, and 1.111 (0.928-1.330) and 1.202 (0.933-1.550), respectively, for OS.CONCLUSION: The DFI is of prognostic value for predicting disease recurrence following surgical treatment of CRLM, but not for predicting OS outcomes.

Published
2019

23. A Software Tool for Advanced MRgFUS Prostate Therapy Planning and Follow Up.

Author

van Straaten, Dörte, Hoogenboom, Martijn, van Amerongen, Martinus J., Weiler, Florian, Al Issawi, Jumana, Günther, Matthias, Fütterer, Jurgen, and Jenne, Jürgen W.

Subjects
PROSTATE cancer patients, PROSTATE cancer treatment, ULTRASONIC therapy, HIGH-intensity focused ultrasound, ABLATION techniques
Abstract

US guided HIFU/FUS ablation for the therapy of prostate cancer is a clinical established method, while MR guided HIFU/FUS applications for prostate recently started clinical evaluation. Even if MRI examination is an excellent diagnostic tool for prostate cancer, it is a time consuming procedure and not practicable within an MRgFUS therapy session. The aim of our ongoing work is to develop software to support therapy planning and post-therapy follow-up for MRgFUS on localized prostate cancer, based on multi-parametric MR protocols. The clinical workflow of diagnosis, therapy and follow-up of MR guided FUS on prostate cancer was deeply analyzed. Based on this, the image processing workflow was designed and all necessary components, e.g. GUI, viewer, registration tools etc. were defined and implemented. The software bases on MeVisLab with several implemented C++ modules for the image processing tasks. The developed software, called LTC (Local Therapy Control) will register and visualize automatically all images (T1w, T2w, DWI etc.) and ADC or perfusion maps gained from the diagnostic MRI session. This maximum of diagnostic information helps to segment all necessary ROIs, e.g. the tumor, for therapy planning. Final therapy planning will be performed based on these segmentation data in the following MRgFUS therapy session. In addition, the developed software should help to evaluate the therapy success, by synchronization and display of pre-therapeutic, therapy and follow-up image data including the therapy plan and thermal dose information. In this ongoing project, the first stand-alone prototype was completed and will be clinically evaluated. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

24. Development of a high-field MR-guided HIFU setup for thermal and mechanical ablation methods in small animals

Author

Hoogenboom, Martijn, primary, van Amerongen, Martinus J., additional, Eikelenboom, Dylan C., additional, Wassink, Melissa, additional, den Brok, Martijn H., additional, Hulsbergen-van de Kaa, Christina, additional, Dumont, Erik, additional, Adema, Gosse J., additional, Heerschap, Arend, additional, and Fütterer, Jurgen J., additional

Published
2015
Full Text
View/download PDF

25. Software-supported analysis of MRgFUS therapy outcome

Author

Corr, Doerte, primary, Weiler, Florian, additional, Hoogenboom, Martijn, additional, van Amerongen, Martinus J., additional, Fütterer, Jurgen, additional, Dadakova, Tetiana, additional, Bock, Michael, additional, Günther, Matthias, additional, and Jenne, Jürgen, additional

Published
2015
Full Text
View/download PDF

28. First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.

Author

Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Hermans JJ, Molenaar IQ, Grünhagen DJ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, May AM, Swijnenburg RJ, and Punt CJA

Abstract

Importance: In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus bevacizumab increased progression-free survival, response, and R0/R1 resection/ablation rates, as well as toxic effects in RAS/BRAFV600E-variant and/or right-sided tumors. FOLFOX/FOLFIRI-panitumumab vs FOLFOX/FOLFIRI-bevacizumab increased response at the cost of more toxic effects in RAS/BRAFV600E wild-type, left-sided tumors., Objective: To present long-term outcomes of treatment with FOLFOXIRI plus bevacizumab vs FOLFOX/FOLFIRI plus bevacizumab and FOLFOX/FOLFIRI plus panitumumab vs FOLFOX/FOLFIRI + bevacizumab., Design, Setting, and Participants: The randomized phase 3 CAIRO5 trial included patients with initially unresectable CRLM in 46 Dutch centers and 1 Belgian center between November 2014 and January 2022. A liver expert panel repeatedly evaluated resectability., Intervention: Patients with RAS/BRAFV600E-variant and/or right-sided tumors randomly received FOLFOX/FOLFIRI-bevacizumab (group 1) or FOLFOXIRI-bevacizumab (group 2), and those with RAS/BRAFV600E wild-type, left-sided tumors received FOLFOX/FOLFIRI-bevacizumab (group 3) or FOLFOX/FOLFIRI-panitumumab (group 4). Adjuvant chemotherapy (ACT) after complete local treatment was recommended but not standard., Main Outcomes and Measures: Overall survival (OS) was analyzed as a secondary outcome. Other outcomes were post hoc analyses., Results: A total of 530 patients (327 male [62%] and 203 female individuals [38%]; median age, 62 [IQR, 54-69] years) were randomized: 148 in group 1, 146 in group 2, 118 in group 3, and 118 in group 4. The median OS in group 1 was 23.6 (95% CI, 20.1-27.5) vs 24.1 (95% CI, 21.0-30.9) months in group 2 (hazard ratio [HR], 0.90; 95% CI, 0.70-1.17; P = .44), and 39.9 (95% CI, 30.7-44.6) in group 3 vs 38.3 (95% CI, 35.3-51.3) months in group 4 (HR, 0.95; 95% CI, 0.68-1.32; P = .75). OS was longest after complete local treatment without early (≤6 months) recurrence (64.3 months; 95% CI, 57.6 to not reached) and salvage local treatment options after early recurrence (58.9; 95% CI, 47.3 to not reached), followed by patients without salvage local treatment after early recurrence (30.5; 95% CI, 24.4-33.4) and with incomplete local treatment (28.7; 95% CI, 25.9-38.3), and worst in patients with continued unresectability (18.3; 95% CI, 15.7-20.0). After confounder adjustment, ACT was associated with longer OS (HR, 0.66; 95% CI, 0.44-0.98) and relapse-free survival (HR, 0.65; 95% CI, 0.48-0.88) and less early recurrence without salvage local treatment (odds ratio, 0.46; 95% CI, 0.25-0.85)., Conclusions and Relevance: These results support using FOLFOX/FOLFIRI-bevacizumab for patients with initially unresectable CRLM irrespective of RAS/BRAFV600E status and tumor sidedness. Patients with complete local liver treatment with salvage local treatment in case of early recurrence had the longest OS. ACT might be considered for these patients., Trial Registration: ClinicalTrials.gov NCT02162563.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results